BMS says Hengrui’s Abraxane infringes

13-05-2022

Alex Baldwin

BMS says Hengrui’s Abraxane infringes

nitpicker / Shutterstock.com

A subsidiary of Bristol-Myers Squibb has sued Chinese pharma company Jiangsu Hengrui Pharmaceuticals, alleging that the company’s planned generic of cancer medication Abraxane (paclitaxel) infringes a patent.


Bristol-Myers Squibb, Jiangsu Hengrui Pharmaceuticals, Abraxane, US District Court of New Jersey, US Food and Drug Administration, generics

LSIPR